Opinion|Videos|March 6, 2026
Toxicity Considerations With ADCs and Other Approaches in EGFR-Mutated NSCLC
Author(s)Joel Neal, MD, PhD, Sarah B. Goldberg, MD, MPH
Joel Neal, MD, PhD, and Sarah Goldberg, MD, MPH, discuss toxicity considerations with ADCs and emerging therapies in EGFR-mutated NSCLC.
Advertisement
Episodes in this series
Joel Neal, MD, PhD, and Sarah Goldberg, MD, MPH, review safety considerations associated with antibody-drug conjugates such as datopotamab deruxtecan (Dato-DXd) and other emerging therapies in EGFR-mutated NSCLC. Neal discusses the management of key toxicities associated with Dato-DXd. Goldberg underscores the importance of early recognition and multidisciplinary management to minimize serious adverse outcomes while preserving clinical benefit.
Advertisement
Related to this article
A pilot study represents a milestone toward testing a faster, more powerful, and potentially less-toxic form of radiation therapy for cancer treatment.
Oral azacitidine and cedazuridine met the end point of total cycle azacitidine exposure vs subcutaneous azacitidine in MDS or CMML.
UTRxMYCN M1-14 received orphan drug status for soft tissue sarcoma and RPDD for rhabdomyosarcoma.
Interim data showed that the BCMA-directed CAR T-cell therapy NXC-201 generated complete responses in relapsed/refractory AL amyloidosis.
Estelamari Rodriguez, MD, MPH, discusses the rationale, design, and practice implications of the phase 3 RELATIVITY-1093 trial in nonsquamous NSCLC.
Experts spotlight the variety of breast cancer research being presented at the 2026 ESMO Congress.
The third BLA submission for tabelecleucel follows 2 CRLs and includes updated ALLELE data with additional patients and longer follow-up.
A New England Journal of Medicine report describes complete hepatoblastoma regression in a 3-year-old treated with a novel immunotherapy.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Plinabulin Plus Docetaxel in Post-ICI Non-Squamous NSCLC
2
Breast Cancer Experts Highlight Abstracts to Watch at ESMO 2026
3
FDA Approves Denosumab Biosimilar for Skeletal-Related Events, GCTB, and Hypercalcemia of Malignancy
4
Navigating DLL3-Targeting T-Cell Engagers and the Evolving Small Cell Lung Cancer Treatment Landscape
5